Ojjaara (Momelotinib) for Myeloproliferative Neoplasms

Overview
Ojjaara is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with myelofibrosis (MF) and anemia (low red blood cell count). Ojjaara may be recommended to treat intermediate or high-risk primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Ojjaara is also referred to by its drug name, momelotinib.

Ojjaara is part of a class of drugs known as Janus kinase inhibitors. Ojjaara is believed to block the activity of enzymes (proteins that speed up chemical reactions) known as Janus kinases. In many types of cancer, Janus kinases are involved in cancer cell proliferation. Blocking their activity can cause cancer cells to die.

How do I take it?
Prescribing information states that Ojjaara is taken orally once daily.

Ojjaara is available in the form of a tablet.

Side effects
The FDA-approved label for Ojjaara lists common side effects including unusual bleeding, bacterial infection, fatigue, dizziness, diarrhea, nausea, and changes in blood cell counts.

Rare but serious side effects listed for Ojjaara include infections, liver damage, dangerous blood clots, severe cardiovascular problems, and an increased risk of developing other types of cancer.

For more details about this treatment, visit:

Ojjaara — GSK
https://ojjaara.com